Subscribe
shutterstock_613544495-atmosphere1
Atmosphere1 / Shutterstock.com
25 June 2019Big Pharma

Fed Circuit sides with Merck in antifungal treatment dispute

A US court has upheld a decision that eight claims of one of Mayne Pharma’s patents are unpatentable for obviousness over prior art after a validity challenge was brought by a subsidiary of Merck & Co.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Fed Circuit sides with Gilead over hep C patent
31 October 2019   The US Court of Appeals for the Federal Circuit has delivered a blow for Merck in a patent infringement dispute against Gilead, upholding one of its patents as invalid.
Americas
Merck boosts oncology pipeline with $1bn deal
22 May 2019   Merck has announced plans to acquire Peloton Therapeutics, a clinical-stage biopharmaceutical company, in a $1.05 billion bid to boost its oncology pipeline.


Editor's picks

AstraZeneca unit faces class-action suit over alleged Soliris monopoly
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025

Editor's picks

Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025
Americas
Trouble at the USPTO—Part II: Bracing for impact
13 March 2025
Americas
‘We need the top 50 law firms to stand up’: Will Perkins Coie ignite Trump resistance?
13 March 2025
Americas
Trouble at the USPTO—Part I: Why government cutbacks are making everyone nervous
6 March 2025
Americas
‘Lift as you climb’: Abbott, BMS, Hitachi, LEGO Group counsels explore ‘empowerment’
6 March 2025
Careers
Jones Day adds experienced patent litigators from Weil
4 March 2025

More on this story

Big Pharma
Fed Circuit sides with Gilead over hep C patent
31 October 2019   The US Court of Appeals for the Federal Circuit has delivered a blow for Merck in a patent infringement dispute against Gilead, upholding one of its patents as invalid.
Americas
Merck boosts oncology pipeline with $1bn deal
22 May 2019   Merck has announced plans to acquire Peloton Therapeutics, a clinical-stage biopharmaceutical company, in a $1.05 billion bid to boost its oncology pipeline.

More on this story

Big Pharma
Fed Circuit sides with Gilead over hep C patent
31 October 2019   The US Court of Appeals for the Federal Circuit has delivered a blow for Merck in a patent infringement dispute against Gilead, upholding one of its patents as invalid.
Americas
Merck boosts oncology pipeline with $1bn deal
22 May 2019   Merck has announced plans to acquire Peloton Therapeutics, a clinical-stage biopharmaceutical company, in a $1.05 billion bid to boost its oncology pipeline.

More features

South Korean firm sues in UK over CRISPR/Cas9 blood disorder drug
Patent litigator with biotech and medical device background joins Sterlington
Resilience and the power of brands: Elisabeth Stewart-Bradley on 9/11, inclusion and the INTA presidency
Fenwick establishes new Boston office with trio of IP partners from Cooley
How pharma should prep for the six-bill avalanche from Congress
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
USPTO speeds up patent issuance amid widespread agency changes
Lathrop GPM adds portfolio management specialist